TY  - GEN
AU  - Weiss,Glen J
AU  - Infante,Jeffrey R
AU  - Chiorean,E Gabriela
AU  - Borad,Mitesh J
AU  - Bendell,Johanna C
AU  - Molina,Julian R
AU  - Tibes,Raoul
AU  - Ramanathan,Ramesh K
AU  - Lewandowski,Karen
AU  - Jones,Suzanne F
AU  - Lacouture,Mario E
AU  - Langmuir,Virginia K
AU  - Lee,Hank
AU  - Kroll,Stew
AU  - Burris,Howard A
TI  - Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
SN  - 1557-3265
PY  - 2011///0915
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Cell Hypoxia
KW  - drug effects
KW  - Disease Progression
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Models, Biological
KW  - Neoplasms
KW  - drug therapy
KW  - Nitroimidazoles
KW  - Phosphoramide Mustards
KW  - Prodrugs
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-10-3425
ER  -